TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab

Publication Date

2026

Content Type

article

PubMed ID:

41793309

Additional Authors:

Additional Authors and Institutional Affiliations

This document is currently not available here.

Share

COinS